Literature DB >> 23556069

Novel therapies for Hodgkin Lymphoma.

John W Sweetenham.   

Abstract

In recent years, improved understanding of the biology of Hodgkin Lymphoma (HL) has uncovered many potential targets for the treatment of this disease. Clarification of the B-ceLL origin of the Hodgkin Reed Sternberg (HRS) cell and of the complex interactions between the HRS cell and the HL microenvironment have provided new insights into the pathophysiology of HL and identified extracellular and intracellular molecules which are essential for HRS survival. New agents directed at these molecules are now in early phase clinical trials.

Entities:  

Keywords:  Hodgkin Lymphoma; new agents; targeted therapy

Year:  2010        PMID： 23556069      PMCID： PMC3573386          DOI： 10.1177/2040620710387980

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  33 in total

1.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

Authors:  A van den Berg; L Visser; S Poppema
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Authors:  Evert M Noordijk; Patrice Carde; Noëlle Dupouy; Anton Hagenbeek; Augustinus D G Krol; Johanna C Kluin-Nelemans; Umberto Tirelli; Mathieu Monconduit; José Thomas; Houchingue Eghbali; Berthe M P Aleman; Jacques Bosq; Marjeta Vovk; Tom A M Verschueren; Anne-Marie Pény; Théodore Girinsky; John M M Raemaekers; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.

Authors:  Boris Böll; Hinrich Hansen; Friederike Heuck; Katrin Reiners; Peter Borchmann; Achim Rothe; Andreas Engert; Elke Pogge von Strandmann
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

4.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.

Authors:  Roberto R Rosato; Jorge A Almenara; Steven Grant
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

5.  Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.

Authors:  Kenneth G Lucas; Donna Salzman; Alejandro Garcia; Qi Sun
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

6.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

7.  Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Authors:  Kristie A Blum; Jeffrey L Johnson; Donna Niedzwiecki; George P Canellos; Bruce D Cheson; Nancy L Bartlett
Journal:  Leuk Lymphoma       Date:  2007-07

8.  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Authors:  Holger Schulz; Ute Rehwald; Franck Morschhauser; Thomas Elter; Christoph Driessen; Thomas Rüdiger; Peter Borchmann; Roland Schnell; Volker Diehl; Andreas Engert; Marcel Reiser
Journal:  Blood       Date:  2007-10-15       Impact factor: 22.113

9.  A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

Authors:  Roland Schnell; Oliver Staak; Peter Borchmann; Christine Schwartz; Bärbel Matthey; Hinrich Hansen; John Schindler; Victor Ghetie; Ellen S Vitetta; Volker Diehl; Andreas Engert
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

10.  Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Authors:  Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.